Results 291 to 300 of about 146,874 (392)

Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double‐blind, randomized controlled DHA‐WIN trial

International Journal of Cancer, Volume 157, Issue 7, Page 1405-1419, 1 October 2025.
What's New? Omega‐3 docosahexaenoic acid (DHA) has shown pleiotropic anti‐cancer effects both in vitro and in animal models. However, clinical evidence of DHA efficacy is limited. This randomized, double‐blind, placebo‐controlled trial tested the efficacy of supplementation with DHA 4.4 g/day during 18 weeks of breast cancer neoadjuvant chemotherapy ...
Jaqueline Munhoz, Marnie Newell, Gilbert Bigras, Susan Goruk, Anil Abraham Joy, Sunita Ghosh, Kerry S. Courneya, Vera Mazurak, Claire M. Douglas, Xiaofu Zhu, Bohdarianna Zorniak, John Mackey, Judith Meza Junco, Julie Price Hiller, Karen King, Sanraj K. Basi, Catherine J. Field   +16 more
wiley   +1 more source

Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment. [PDF]

Ther Adv Med Oncol
Liu YS, Barner JC, Lawson KA, Liu Y, Park C.   +4 more
europepmc   +1 more source

Cancer in pregnancy: FIGO Best practice advice and narrative review

International Journal of Gynecology &Obstetrics, Volume 171, Issue 1, Page 131-151, October 2025.
Abstract Cancer during pregnancy is relatively rare. The incidence is underestimated due to the lack of international registries covering both high‐income and low‐ and middle‐income countries, and is expected to rise with increasing maternal age and increasing global adoption of cell‐free DNA testing for aneuploidy.
Surabhi Nanda, Melanie Nana, Long Nguyen‐Hoang, Sumaiya Adam, Fionnuala McAuliffe, Lina Bergman, Sarikapan Wilailak, Orla McNally, Cynthia V. Maxwell, Nikhil Purandare, Bo Jacobsson, Virna P. Medina, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Ernesto Castelazo, Graeme N. Smith, Sharleen L. O'Reilly, Patrick O'Brien, Mark Hanson, Mary L. Rosser, Claudio Sosa, Valerie Guinto, Jonathan Berek, Catherine Nelson‐Piercy, Frédéric Amant, Liona Poon, on behalf of the FIGO Committee on the Impact of Pregnancy on Long‐term Health, FIGO Committee on Women's Cancer, and the FIGO Division of Maternal and Newborn Health   +29 more
wiley   +1 more source

Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification

, 2005
Javier A. Menéndez, Luciano Vellón, Rámón Colomer, Ruth Lupu   +3 more
openalex   +1 more source

Prognostic factors and survival outcome of brain metastases in breast cancer patients: a retrospective analysis. [PDF]

BMC Cancer
Durrani S, Al-Ghamdi AA, Al-Bugawi A, Al-Khammash A, Al-Hawish M, Dabour K, Al-Obaisi Y, Al-Rashidi S.   +7 more
europepmc   +1 more source

Cancer and fertility management: FIGO best practice advice

International Journal of Gynecology &Obstetrics, Volume 171, Issue 1, Page 32-44, October 2025.
Abstract Cancer diagnoses in patients of reproductive age require balancing urgent oncological treatment with the need to preserve fertility. This FIGO Best Practice Advice outlines key considerations for fertility management in this population given the rising cancer incidence among young women and the reproductive risks posed by cancer treatments ...
Nikhil Purandare, Francisco Ruiloba, Long Nguyen‐Hoang, Sarikapan Wilailak, Nozomu Yanaihara, Jacqueline P. W. Chung, Jaideep Malhotra, Edgar Mocanu, Frédéric Amant, Orla McNally, Inge Peters, Katie Flynn, Aya El Helali, Cynthia Maxwell, Sumaiya Adam, Lina Bergman, Surabhi Nanda, Valerie Tiempo Guinto, Fionnuala M. McAuliffe, Catherine Nelson‐Piercy, Melanie Nana, Graeme Smith, Jonathan Berek, Sharleen O'Reilly, Pat O'Brien, Bo Jacobsson, Liona C. Poon, on behalf of the FIGO Committee on the Impact of Pregnancy on Long‐term Health and the FIGO Division of Maternal and Newborn Health and in collaboration with the FIGO Committee on Women's Cancer and the FIGO Committee on Reproductive Medicine, Endocrinology and Infertility   +28 more
wiley   +1 more source

Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies. [PDF]

Med Sci (Basel)
Fitrianti AE, Wardani NO, Astuti A, Anggadiredja K, Amalia L, Putri RA, Zazuli Z.   +6 more
europepmc   +1 more source

Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

MedComm, Volume 6, Issue 10, October 2025.
In TME, undetectable DCCs (panel A) join with a low tumor burden along with low immune suppression, that favor successful immune manipulation through immune suppression inhibiting immune‐therapy. This moves the immune balance toward the immune response and likely makes more stable the dormant state of DCCs in the unstable metastatic niche and/or allows
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, Dario A. Bini   +3 more
wiley   +1 more source

Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma. [PDF]

Oncol Res
Sungwan P, Panaampon J, Sumankan R, Aoki G, Okada S.   +4 more
europepmc   +1 more source

G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

MedComm, Volume 6, Issue 10, October 2025.
G protein‐coupled receptors (GPCRs) are the dynamic protein family in the human genome. GPCR dysregulation aids in the advancement of cancer through increased migration, survival, and proliferation. Novel treatments that target GPCR signaling include orthosteric ligands, biased receptor mutants, PROTACs, and antibody–drug conjugates.
Inamu Rashid Khan, Sana Khurshid, Saud Almawash, Rakesh Kumar, Ammira S. Al‐Shabeeb Akil, Ajaz A. Bhat, Muzafar A. Macha   +6 more
wiley   +1 more source